A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease

Summary

The primary purpose of this multi-centre, double blind-study is to evaluate the clinical response of patients with moderate to severe Cohn's Disease (CD) following treatment with different doses and dose regimens of Olokizumab, relative to placebo.

Timeline

Start

2012-06

Primary completion

2013-08

Completion

2013-08

Outcome

Outcome not reported

Stopped: “Study was withdrawn due to delay in timelines. There were no safety concerns regarding the study or the compound in the decision to withdraw the trial.”

Drugs

Indications